Despite the significant response of melanoma, non-small-cell lung cancer, and lymphoma patients to PD-1/PD-L1-directed treatments, fewer benefits were observed in patients suffering from other cancer types. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.